Cell and gene therapeutics have revolutionised modern medicine and mark a new generation in biomedical and agricultural sciences. The latest developments in cell and gene therapies and specifically in gene editing, technologies present unlimited research opportunities ranging from novel therapeutic tools to a potential revolution in the field of drug discovery.
This year's event will be led by scientists and clinicians researching, developing and testing new treatments for genetically inherited and acquired diseases using gene delivery technology, stem cell manipulation and DNA repair techniques. The conference will cover all aspects of the subject, including biomedical science principles, molecular basis of disease, current and developing technologies and clinical applications.
The conference will be inviting speakers from global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions Expect over 16 presentations and case studies focused on the key aspects of GMP, bioprocessing, regulatory frameworks and new therapeutic developments in in the field of cell and gene.
2018 FEATURED HIGHLIGHTS:
- Discuss the challenges of accessing patients with commercial ATMPs - Understand the advantages of a risk-based approach to cell and gene therapy manufacturing - Hear the MHRA's perspective of UK and EU regulatory affairs regarding ATMPs - Explore the unique applications of the CRISPR/Cas9 system for drug development at AstraZeneca - Gain insight into GMP Manufacture of plasmid DNA at the NHSBT
Category: Conferences | Science, Health and Medicine
Prices: Standard Price (Early Bird Rates Available Online): GBP 1499.0, REGISTER BY 31ST MAY AND SAVE £400: GBP 1099.0, REGISTER BY 29TH JUNE AND SAVE £300: GBP 1199.0, REGISTER BY 31ST AUGUST AND SAVE £200: GBP 1299.0
Speakers: ** CHAIR FOR 2018: Pamela Tranter, Head of Translational Research Group, UCL **, - Janet Glassford, Senior Quality Assessor (Biologicals), MHRA, - Giuseppe Ronzitti, Cell and Gene Therapy Specialist, Genethon, - Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences, - Shailesh Gupta, Senior Scientist, AstraZeneca, - Peggy Sotiropoulou, RandD Manager, Research and Development, Celyad, - Julie Kerby, Head of Manufacturing Development, Cell and Gene Therapy Catapult, - Lior Raviv, Vice President, Development, Pluristem, - Diego Aridgo, RandD Rare Disease Unit Head, Chiesi, - Mehdi Gasmi, Chief Science and Technology Officer, Adverum Biotech, - Emanuela Cuomo, Associate Director, Discovery Sciences, Cellular Biology Team, AstraZeneca, - Yen Choo, Founder and Executive Chairman, Plasticell, - Ian McKay, Innovation Lead Advanced Therapies, Innovate UK